NIH stopped Study of Niacin
On Thursday the National Institutes of Health (NIH) halted a major study of high-dose niacin, a type of B vitamin, more than a yr forward of schedule as a result of the lack of advantage. It was the newest setback in the quest to harness great cholesterol to combat the negative sort.
The trial, sponsored from the U.S. National Institutes of Health and a drug maker, enrolled patients using a background of heart disease who had their “bad” LDL cholesterol under management with statin medicines. The brand new trial hoped to make use of niacin (also known as vitamin B3) to increase ranges of “good” HDL cholesterol even though lowering blood amounts of fats named triglycerides to assist decrease the odds of heart attack or stroke.
The most recent study tested Abbott Laboratories’ Niaspan, an extended-release sort of niacin that is certainly a far higher dose than is discovered in dietary supplements. The drug has long been marketed for years, and past studies have demonstrated it does improve HDL levels.
Read more detail at:
